MA 11.06 Retrospective Analysis of NSCLC Testing in Low Tumor Content Samples: Single-Gene Tests, NGS, &amp; the Oncomine™ Dx Target Test

Yu, Tsan-Jung; Morrison, C.; Gold, Edward J.; Tradonsky, Alison; Layton, Andrew

doi:10.1016/j.jtho.2017.09.546

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because there is an increasing number of mutations to be analyzed, NGS panels are an attractive approach for ctDNA analysis [15]. NGS panels offer advantages of higher throughput, higher sensitivity, more efficient use of limited tissue, and lower cost per analysis than PCR-based methods [15,44,45]. Foundation-One CDx (Foundation Medicine, Cambridge, MA, USA) is an FDA-approved targeted NGS panel and detects mutations in 324 genes.…”

Section: Current Technologies For Circulating Tumor Dna Detectionmentioning

confidence: 99%

Current status and future perspectives of liquid biopsy in non-small cell lung cancer

Chang

Hur

Choi

et al. 2020

J Pathol Transl Med

View full text Add to dashboard Cite

Molecular analysis is traditionally performed on tumor tissue. Although the number of mandatory tests for treatment decisions increases in patients with advanced non-small cell lung cancer (NSCLC), it is difficult to secure adequate tumor tissue for this purpose [1]. Small biopsy specimens, cell blocks, or aspirates are often the only available samples in patients with advanced NSCLC [2,3]. It is difficult to repeat tissue biopsies because they are invasive. Liquid biopsy could be an alternative or a complementary minimally invasive method for detecting molecular changes in NSCLC [1,2,4,5]. The clinical use of liquid biopsy to select patients with advanced NSCLC who are candidates for third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy has been demonstrated in many clinical trials [6-10]. The United States Food and Drug Administration (FDA) approved Cobas EGFR Mutation Test v2 (Roche, Indianapolis, IN, USA) in 2018 as a companion diagnostic for third-generation EGFR TKI based on these results [11]. The Korea National Health Insurance Service (NHIS) has covered circulating cell-free tumor DNA (ctDNA) tests for EGFR mutations in advanced NSCLC since 2018. In this review, we present the current status and future perspectives of liquid biopsy in patients with NSCLC. BIOLOGY OF CIRCULATING TUMOR DNA Liquid biopsy refers to the collection and analysis of analytes from various body fluids such as blood, urine, sputum, and pleural fluid [12-14]. Different analytes can be present in a liquid biopsy including circulating tumor cells (CTCs), circulating cell-free DNAs (cfDNAs), circulating tumor RNAs (ctRNAs), circulating exosomes, tumor-educated platelets, proteins, and metabolites [15,16]. CTCs are intact, viable tumor cells circulating in the blood [12]. Cancer releases single or clusters of CTCs into the bloodstream during the course of hematogenous spread. cfDNA refers to all circulating DNA in body fluids. cfDNA can be derived from neoplastic as well as non-neoplastic cells [15,16]. cfDNA can be detected in other body fluids, including urine, saliva, or cerebrospinal fluid. ctDNA refers to a subgroup

show abstract

Section: Current Technologies For Circulating Tumor Dna Detectionmentioning

confidence: 99%

Current status and future perspectives of liquid biopsy in non-small cell lung cancer

Chang

Hur

Choi

et al. 2020

J Pathol Transl Med

View full text Add to dashboard Cite

show abstract

“…The capacity of the technology to generate a huge amount of biological information required computational and human developments for data analysis 90 . FDA approved the first NGS test for detecting multiple biomarkers from a single sample of lung cancer in 2017 53 , facilitating allocation of advanced NSCLC patients into a guided-treatment based on the results from a single test 91 . Advances in minimally invasive procedures technologies led to an access of smaller tissue fragments.…”

Section: Advances In Molecular Testing Methodologiesmentioning

confidence: 99%

Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges

Ferreira,

Marchi,

Veloso

et al. 2024

MRAJ

View full text Add to dashboard Cite

Precision medicine has revolutionized lung cancer management – particularly non-squamous cell carcinomas – with a broader genomic comprehension and the possibility of offering tailored treatments guided by oncogenic driver mutations – the basis of precision medicine. Since the publication of the IPASS trial in 2009 a new Era of molecular actionability began for lung cancer research and treatment. The remarkable past fifteen years were characterized by advances on genomic testing methodologies, the emergence of new biomarkers and targeted therapies, and the widespread of precision medicine in lung cancer care from advanced to earlier stages – specially for the adenocarcinoma histology, a heterogeneous disease with unprecedent improvements in outcomes. Nonetheless, several barriers need to be overcome with the adoption of cutting-edge technologies, such as the high cost of new diagnostic and therapeutical technologies and their discrepant accessibility, mainly in low- and middle-income countries. Moreover, there is still a lack of clear clinical actionability for squamous cell carcinoma and small cell lung cancer in which ideal biomarkers are yet to be discovered and validated. Herein, we aimed to discuss several aspects on how precision medicine positively impacted on lung cancer management and the lessons learned. Additionally, we scoped future perspectives on precision oncology in lung cancer as technology advances.

show abstract

“…Thus, a gene panel testing becomes an attractive approach. A number of next-generation sequencing based gene panels are currently available for tissue samples (34)(35)(36). Such gene panel approach is also applicable in the setting of liquid biopsy (19).…”

Section: Liquid Biopsy In Detecting Tumor-derived Circulating Cfdna-diagnostic Potentialmentioning

confidence: 99%

Latest development of liquid biopsy

Cheung

Chow

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Liquid biopsy provides the opportunity of detecting and analyzing cancer in various body fluids. In peripheral blood, apart from circulating cell free DNA, circulating cancer cells and other tumor-associated compounds such as extracellular vesicles are also emerging candidates for detection. Compared to conventional tissue or cytology samples, liquid biopsy is non-invasive, safe, and easy to repeat. In view of tumor heterogeneity, it is also suggested that circulating cell free DNA may be more representative of the whole tumor cells population than a biopsy or cytology sample. In addition to assisting in the initial diagnosis, liquid biopsy can also be tailored for disease monitoring, detecting resistance mutation, tumor recurrence, and perhaps for screening in the future. The accuracy of this test is greatly facilitated by the advances of molecular techniques, from PCR-based methods, DNA sequencing, Digital PCR, to the more state-of-the-art next generation sequencing technologies. Despite the tremendous potential of liquid biopsy, there are limitations and not all clinical relevant cancer biomarkers can be detected in liquid biopsy at the present moment. The clinical utility of many of the tests derived from liquid biopsy required further investigations and clinical validation. This review provides an overview of the concept of liquid biopsy, its clinical applications, and discuss the multifaceted advances in this field.

show abstract

MA 11.06 Retrospective Analysis of NSCLC Testing in Low Tumor Content Samples: Single-Gene Tests, NGS, & the Oncomine™ Dx Target Test

Cited by 6 publications

References 0 publications

Current status and future perspectives of liquid biopsy in non-small cell lung cancer

Current status and future perspectives of liquid biopsy in non-small cell lung cancer

Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges

Latest development of liquid biopsy

Contact Info

Product

Resources

About